Terazosin Capsule
Product Images NDC 50090-2623

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Terazosin (NDC 50090-2623). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500901559)

Terazosin 5 mg oral capsules packaging label from A-S Medication Solutions. The label shows product number 4875-0, a lot number placeholder, storage instructions to store between 68 to 77 degrees Fahrenheit protecting from light and moisture, and a quantity of 30 capsules. The active ingredient is terazosin hydrochloride equivalent to terazosin 5 mg.*

FDA Label Image

Label Image (Lbl500902371)

Terazosin 10 mg capsules packaging label from A-S Medication Solutions. The label indicates a product lot number, storage instructions to keep between 68 to 77 degrees Fahrenheit protected from light and moisture, and a count of 90 capsules. It includes labeler and location details with directions to use as prescribed by a doctor.*

FDA Label Image

Label Image (Lbl500902623)

Terazosin 2 mg oral capsules label from A-S Medication Solutions. The label includes storage instructions to keep at 68 to 77 degrees Fahrenheit, protecting from light and moisture. It contains 30 capsules per package and provides a QR code for dosage and package insert information. Labeler location is Libertyville, IL 60048.*

FDA Label Image

Terazosin Hydrochloride Chemical Structure (Terazosin Hydrochloride Capsules 1)

Chemical structure of Terazosin Hydrochloride, showing the molecular arrangement including aromatic rings, amine groups, and a piperazine moiety linked to a carbamate and tetrahydrofuran ring.*

FDA Label Image

Figure 1 (Terazosin Hydrochloride Capsules 2)

This figure consists of two line graphs comparing Terazosin and placebo over a 3-month period. The left graph shows mean change in total symptom score from baseline, with Terazosin showing greater symptom reduction than placebo. The right graph shows mean increase in peak flow rate (mL/sec) from baseline, with Terazosin demonstrating a higher increase compared to placebo. Both graphs include error bars and sample sizes (N) for each group.*

FDA Label Image

Figure 2 (Terazosin Hydrochloride Capsules 3)

A line graph depicting the mean change from baseline over a 30-month period. The x-axis represents months (0 to 30), and the y-axis shows mean change from baseline values ranging from 0 to -7. Data points are plotted with markers, some indicating statistical significance with asterisks.*

FDA Label Image

Figure 3 (Terazosin Hydrochloride Capsules 4)

A line graph depicting mean change from baseline in a measured variable over a 30-month period. The x-axis represents time in months, while the y-axis shows mean change values. Data points include error bars, with several marked by asterisks indicating statistical significance.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.